Home

Elisabeth Sandoval Little

CIK 1632295 · CCO & EVP, Corporate Strategy · last filed 2026-06-10

Elisabeth Sandoval Little is a CCO & EVP, Corporate Strategy who has filed 32 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for PRCT, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $282.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$282.4K

Companies

7

Total Filings

32

Lifetime Open-Market Net

-$6.51M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PRCT Director 15,876 $17.79 $282.4K $0 6 2026-06-10
VYNE Director — $28.56 — $0 6 2025-12-15
Satsuma Pharmaceuticals, Inc. (STSA) Delisted Director — $1.10 — $0 4 2023-06-08
Intersect ENT, Inc. (XENT) Delisted Director — $28.24 — $0 2 2022-05-16
VYNE Therapeutics Inc. (MNLO) Delisted Director — — — $0 4 2020-08-05
ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted CCO & EVP, Corporate Strategy — — — $0 4 2018-02-21
KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted Chief Commerical Officer 0 — — -$6.51M 6 2015-10-02

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 PRCT Grant (A) +3,315 $0 EDGAR
2025-12-15 VYNE Grant (A) — $0 EDGAR
2025-06-12 PRCT Grant (A) +1,538 $0 EDGAR
2024-12-13 VYNE Grant (A) — $0 EDGAR
2024-06-06 PRCT Grant (A) +1,376 $0 EDGAR
2024-01-03 VYNE Grant (A) — $0 EDGAR
2023-12-15 VYNE Grant (A) — $0 EDGAR
2023-06-16 PRCT Grant (A) +2,711 $0 EDGAR
2023-06-08 Satsuma Pharmaceuticals, Inc. (STSA) Delisted Disp (D) — $0 EDGAR
2022-08-12 VYNE Grant (A) — $0 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.